In a New Study, Treatment With JANUMET® (sitagliptin/metformin), Merck’s Diabetes Medicine, Resulted In Significantly …
In a New Study, Treatment With JANUMET® (sitagliptin/metformin), Merck’s Diabetes Medicine, Resulted In Significantly …
WHITEHOUSE STATION, N.J.—-New data were presented at the American Diabetes Association 70th Annual Scientific Sessions from a study comparing JANUMET to pioglitazone. In this study, JANUMET resulted in significantly greater blood sugar reductions in patients with type 2 diabetes compared with pioglitazone.
Read more on Business Wire via Yahoo! Finance
